Singh, Awadhesh Kumar
Singh, Akriti
RituSingh, Ritu
Misra, Anoop
2020-07-24T19:51:49Z
2020-07-24T19:51:49Z
2020-05-08
1871-4021
https://www.sciencedirect.com/science/article/pii/S1871402120301375?via%3Dihub
http://hdl.handle.net/20.500.12010/11121
8 página
application/pdf
Diabetes & Metabolic Syndrome: Clinical Research & Reviews
reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
Remdesivir
Clinical outcome
Mortality
Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies
Artículo
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/acceptedVersion
https://doi.org/10.1016/j.dsx.2020.05.018
Background & aims
Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19.
Methods
We systematically searched the PubMed, ClinicalTrial.Org and MedRxiv database up till May 5, 2020 using specific key words such as “Remdesivir” or ‘GS-5734″ AND “COVID-19” or “SARS-CoV-2” and retrieved all the article published in English language, that have reported the pharmacology and the clinical outcomes of remdesivir in patients with COVID-19.
Results
Initial compassionate use of remdesivir has shown a fairly good result, but difficult to quantify, in the absence of control arm. While the very first double-blind, placebo-controlled, randomized trial conducted in Wuhan, did not find any significant benefit compared to the control, the preliminary result of another similar multi-country trial has shown a significant faster time to recovery but without any difference in mortality.
Conclusions
Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect. However, jury is still out while awaiting the results from the forthcoming trials.